作者
Christopher Sjöwall,Heinrich Schlums,Lars Gerullat,Jakob Theorell,Tessa Mollie Campbell,Samuel C. C. Chiang,Per Eriksson,Petter S. Woll,Jörg Cammenga,Yenan T. Bryceson
摘要
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome necessitating strong immunosuppression. 1 Familial HLH is associated with defects in lymphocyte cytotoxicity, with defective CD8 + T-cell immunosurveillance of infected cells representing a root cause.However, animal models have also suggested an important role for natural killer (NK)-cell immunoregulatory activity in protecting from disease. 2 NK cells typically express a multitude of receptors implicated in eradicating activated immune cells, but such immunoregulatory activity is lacking in adaptive NK cells that can dominate in individuals infected with cytomegalovirus (CMV).3 VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a condition characterized by severe inflammatory manifestations caused by somatic hematopoietic mutations in the X-linked Ubiquitin-like modifier-activating enzyme (UBA1) gene, typically caused by amino acid substitutions of methionine at codon 41. 4 These mutations impair cytoplasmic E1-ubiquitin ligase activity, causing inflammation and driving clonal expansion.4,5 VEXAS syndrome has an estimated prevalence of 1:14 000 individuals, but is likely higher in males aged >50 years.6 Three cases of VEXAS syndromeassociated HLH have previously been reported but the pathophysiological mechanisms remain elusive.[7][8][9] Herein, we report 2 additional cases of VEXAS syndrome developing HLH, 1 fatal and another successfully treated.In-depth NK-cell analyses of these patients with VEXAS syndrome provide novel pathophysiological insights into HLH susceptibility.Patient A, a previously healthy male aged 63 years, was referred to the Rheumatology Unit at Linköping University Hospital on the suspicion of a periodic fever syndrome in 2007.Febrile episodes had started 1 year before referral, and the patient lacked any family history of fever syndromes or rheumatic diseases.Examinations excluded infections, malignancy, or vasculitis.A skin biopsy obtained during a fever attack revealed leukocytoclastic vasculitis with mainly neutrophils without depositions of immunoglobulins or complement.A fever syndromes gene panel revealed a heterozygous TNFRSF1A c.362G>A (p.R92Q) variant weakly associated with tumor necrosis factor receptor-associated periodic fever syndrome.10 The patient developed leukopenia (1.8 × 10 9 /L, mostly lymphopenia), which persisted after discontinuation of colchicine.He further developed thrombocytopenia (<80 × 10 9 /L) and macrocytic anemia.He was Epstein-Barr virus (EBV) and CMV immunoglobulin G seropositive, and displayed intermittent reactivation of EBV with ≤2810 copies per mL.Two bone marrow biopsies revealed increased plasma cells, a left-shifted myelopoiesis, but no signs of myeloma, myeloproliferative neoplasm, or hemophagocytosis.The patient's symptoms were managed with prednisolone 30 mg/d, but hematological parameters deteriorated (supplemental Figure 1).Erythrocyte sedimentation rate and C-reactive protein remained high, and the patient continued to suffer from fever